This trial tests an experimental treatment using reduced cyclophosphamide, abatacept, and tacrolimus to prevent GvHD in adult patients with hematological malignancies undergoing allogeneic HSCT.
- Graft-versus-Host Disease
1 Primary · 8 Secondary · Reporting Duration: Up to Day 730
Awards & Highlights
1 Treatment Group
Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tac...
1 of 1
92 Total Participants · 1 Treatment Group
Primary Treatment: Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 100 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any remaining openings in this medical trial?
"According to information presented on clinicaltrials.gov this experiment is in the recruitment phase of its cycle. The trial was initially announced on August 23rd 2022 and its most recent update occurred November 10th 2022." - Anonymous Online Contributor
Is there an age cap for enrollment in this research project?
"Patients aged 18-100 are eligible to participate in this medical trial. An additional 63 studies have been established for minors, while 145 other studies accept applicants above the age of 65." - Anonymous Online Contributor
What is the current enrollment limit for participants in this investigation?
"Indeed, the details available on clinicaltrials.gov demonstrate that this medical study is actively recruiting participants. It was initially posted August 23rd 2022 and has since been revised November 10th of the same year. Currently, 92 individuals are needed to participate from a single site." - Anonymous Online Contributor
Has the FDA approved a regimen of Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus?
"As it is only in its second phase of clinical trials, there exists some evidence confirming the safety of Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept and Short-Duration Tacrolimus but no information on efficacy so far. Therefore, we have assigned this drug a rating of 2." - Anonymous Online Contributor
Am I eligible to partake in this clinical investigation?
"Admission to this medical trial is available for those aged 18-100 suffering from a specified condition. As of right now, 92 potential participants have been identified." - Anonymous Online Contributor